Developing best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases
Vaxcyte (formerly SutroVax) is a vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases. The company is leveraging an exclusive license to Sutro Biopharma’s Xpress cell-free protein synthesis platform to develop vaccines with heightened immunity and broader protection than can be attained with existing platforms. Vaxcyte’s lead program is a potentially best-in-class pneumococcal conjugate vaccine (PCV) to prevent invasive pneumococcal disease.
